Background Traditionally, acromegaly evaded diagnosis until in its clinically obvious later
stages when treatment is more difficult. Over the last 25 years diagnostic tests have …

Object Using strict biochemical remission criteria, the authors assessed surgical outcomes
after endoscopic transsphenoidal resection of growth hormone (GH)–secreting pituitary …

Impaired glucose tolerance and diabetes mellitus are a manifestation of several well
recognised endocrine disorders. Hyperglycaemia subsides upon removal of the underlying …

Hipertensão Arterial Sistêmica Secundária inibidora da síntese de catecolaminas: a
alfametiltirosina (Demser®). Para a intervenção cirúrgica, recomenda-se controle da PA …

Growth hormone (GH) is listed in the 2008 Prohibited List (http://www. wada-ama.
org/rtecontent/document/2008_List_En. pdf) because of its theoretical potential to enhance …

This chapter deals with non-vascular intracranial disorders resulting in headache.
Headache attributed to high or low cerebrospinal fluid pressure is separated into headache …

OBJECTIVE: To evaluate the frequency of subclinical acromegaly (in the absence of clinical
phenotype but biochemically uncontrolled) in patients with prolactinoma during treatment …

Introduction: The incidence rate of acromegaly is 50 to70 persons per one million people. It
occurs twice as often in women than in men, especially in middle age. In the course of the …

Introducción: La prevalencia internacional de la acromegalia es de 40 a 60 casos por millón
de habitantes. En México no existen cifras oficiales en cuanto a la frecuencia de esta …

É um grupo de doenças nas quais a produção de aldosterona está aumentada de uma
forma relativamente autônoma em relação ao sistema renina-angiotensina, não sendo …